| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 36.47 | 6.23% | 23.21万 | 8.50亿 | | 301201 | 诚达药业 | 32.78 | 3.15% | 6.10万 | 2.00亿 | | 000504 | *ST生物 | 9.01 | 1.69% | 2.13万 | 1897.70万 | | 600568 | ST中珠 | 1.86 | 1.09% | 18.02万 | 3348.58万 | | 301096 | 百诚医药 | 58.39 | 0.46% | 3.39万 | 1.98 Z | | 300015 | 爰尔眼科 | 12.55 | 0.24% | 87.10万 | 10.92亿 | | 002172 | 澳洋健康 | 4.04 | -0.49% | 18.35万 | 7467.58万 | | 301060 | 兰卫医学 | 9.13 | -0.87% | 2.55万 | 2350.22万 | | 688046 | 药康生物 ...

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：公司回复脑机手术用聚乙二醇复合国家标准，那么请 问公司脑机用聚乙二醇是来自仅有认证的奥克股份吗？ 三博脑科（301293.SZ）10月17日在投资者互动平台表示，您好！目前三博脑科仅福建院区开展过一例 介入式脑机接口手术，该手术中用到的具体产品信息属于合作各方保密信息，感谢您的关注。 ...

Core Insights - Neuromodulation technology shows significant advantages in treating neurological diseases such as epilepsy and Parkinson's disease, enhancing treatment effectiveness and improving patients' quality of life [1][8] - The Chinese neuromodulation industry is projected to reach a market size of approximately 2.285 billion yuan in 2024, reflecting a year-on-year growth of 8.65%, driven by technological innovation and market demand [1][8] Industry Overview - Neuromodulation is a treatment method that regulates nervous system activity through electrical, magnetic, chemical, or other forms of stimulation, aiming to alleviate symptoms and improve functionality [2] - The industry can be categorized into invasive and non-invasive techniques, each comprising various specific technologies [2] Industry Development History - The Chinese neuromodulation industry has evolved over seventy years, starting from foundational research in the 1950s to the current stage of mature expansion, with significant milestones in technology introduction and innovation [2][3] - Key developments include the first DBS surgery in 1998 and the establishment of the first domestic DBS product registration in 2013, marking a shift from technology importation to independent innovation [2][3] Market Size - The neuromodulation market is expected to grow to approximately 2.285 billion yuan in 2024, with an 8.65% increase from the previous year, indicating a dual driving effect of technology transformation and market demand [1][8] Key Companies - Beijing Pincai Medical holds over 25% of the domestic market share with its comprehensive range of neuromodulation products, including DBS and SCS [9][10] - Suzhou Jingyu Medical is a leading player in the DBS field, having received FDA breakthrough device designation for its dual-target DBS technology [10][11] Industry Development Trends 1. Continuous integration of technological innovations will drive precision and intelligent upgrades in the neuromodulation sector, with advancements in AI and brain-computer interfaces expected to enhance treatment efficacy [12] 2. Application scenarios are expanding from traditional disease treatment to cognitive enhancement and emotional regulation, with consumer-grade neuromodulation devices anticipated to see explosive growth [13][14] 3. Policy and industry collaboration will promote domestic production and global expansion, with ongoing government support for brain science initiatives and the inclusion of neuromodulation procedures in insurance reimbursement [15]

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

Investment Rating - The report suggests focusing on companies with "technical barriers + clinical landing" as the dual main lines for investment, recommending attention to medical scene integrators and leaders in invasive technology [4]. Core Insights - The brain-computer interface (BCI) industry is driven by both policy and technology, with a market expected to grow from $1.2 billion in 2019 to $2 billion in 2023, and projected to reach $7.63 billion by 2029, indicating a compound annual growth rate (CAGR) of 17.5% from 2024 to 2029 [3][24]. - The medical sector is currently the most mature application area for BCI, with 31 clinical trials planned in 2024 covering various diseases, and the integration of medical and consumer applications is expected to create a dual growth curve [3][54]. - The domestic industry chain is becoming more self-sufficient, with significant advancements in invasive BCI technologies, and several regions are expected to form industrial clusters [4][27]. Summary by Sections Industry Overview - BCI technology is a frontier field at the intersection of life sciences and information technology, creating interactive systems between the brain and external devices [14][16]. - The global BCI market is projected to grow significantly, with a forecasted market size of $7.63 billion by 2029, reflecting a CAGR of 17.5% from 2024 to 2029 [24][25]. - The industry is currently in a technology validation phase, with active investment activities, particularly in China, where over 200 financing events have occurred, totaling nearly $2 billion [27][29]. Policy Guidance - The Chinese government has issued several policies to support the BCI industry, aiming for technological breakthroughs by 2027 and the establishment of a robust industrial ecosystem by 2030 [42][43]. - The regulatory framework is evolving, with ongoing efforts to ensure safety, effectiveness, and ethical compliance in BCI technology [45][47]. Clinical Situation - Stroke is identified as the primary indication for BCI applications, with a significant patient population in need of rehabilitation solutions [54][59]. - The number of clinical trials related to BCI is increasing, with 31 trials registered in 2024, indicating a growing interest in the clinical potential of BCI technologies [65][66].

三博脑科（301293.SZ）9月24日在投资者互动平台表示，公司脑机接口还处于实验性开展和实验室验证 阶段，距离成熟应用还有一系列验证过程。目前不会对公司产生较大影响。 （记者 谭玉涵） 每经AI快讯，有投资者在投资者互动平台提问：脑机接口纳入医保，会对贵公司产生什么影响？ ...

Core Viewpoint - Sanbo Brain Science experienced a decline of 1.39% in stock price on September 23, with a trading volume of 525 million yuan, indicating potential volatility in the stock market performance [1]. Financing Summary - On September 23, Sanbo Brain Science had a financing buy-in amount of 60.30 million yuan and a financing repayment of 63.94 million yuan, resulting in a net financing outflow of 3.64 million yuan [1]. - As of September 23, the total financing and securities lending balance for Sanbo Brain Science was 639 million yuan, with the financing balance accounting for 6.89% of the circulating market value, indicating a high level of financing activity [1]. - The company had a securities lending repayment of 1,300 shares and a securities lending sell-out of 12,700 shares, with a sell-out amount of 730,100 yuan, reflecting significant trading activity in the securities lending market [1]. Company Performance - As of June 30, the number of shareholders for Sanbo Brain Science reached 43,200, an increase of 14.69% compared to the previous period, while the average circulating shares per person decreased by 12.81% to 3,725 shares [2]. - For the first half of 2025, Sanbo Brain Science reported an operating income of 827 million yuan, representing a year-on-year growth of 17.54%, and a net profit attributable to shareholders of 69.70 million yuan, up 4.60% year-on-year [2]. Dividend and Shareholding Structure - Since its A-share listing, Sanbo Brain Science has distributed a total of 45.10 million yuan in dividends [3]. - As of June 30, 2025, the second-largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 4.81 million shares as a new shareholder, while the Southern Zhongzheng 1000 ETF increased its holdings by 249,800 shares to 1.33 million shares [3].

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Group 1 - The company, Sanbo Brain Science, announced the establishment of a new investment fund to enhance its industry chain and expand its business scale [2] - The fund aims to improve the company's medical service technology level and core competitiveness by leveraging the expertise of professional investment institutions [2] - The fund, named Shanghai Delian Bojian Venture Capital Partnership, has been officially registered with the Asset Management Association of China [2]